Eton Pharmaceuticals Files 8-K with ET-700 Update

Ticker: ETON · Form: 8-K · Filed: Apr 27, 2026 · CIK: 0001710340

Eton Pharmaceuticals, Inc. 8-K Filing Summary
FieldDetail
CompanyEton Pharmaceuticals, Inc. (ETON)
Form Type8-K
Filed DateApr 27, 2026
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: 8-K, regulatory-filing, product-update

TL;DR

Eton Pharma dropped an 8-K on ET-700, check the press release.

AI Summary

Eton Pharmaceuticals, Inc. filed an 8-K on April 27, 2026, to report on other events. The filing includes a press release related to ET-700, which is detailed in Exhibit 99.1.

Why It Matters

This filing provides an update on Eton Pharmaceuticals' product ET-700, which could impact its future development and market position.

Risk Assessment

Risk Level: low — The filing is an informational update and does not appear to contain significant new risks or material adverse events.

Key Players & Entities

  • Eton Pharmaceuticals, Inc. (company) — Filer of the 8-K report
  • ET-700 (product) — Subject of the press release included in the filing
  • April 27, 2026 (date) — Filing date of the 8-K

FAQ

What is the nature of the press release included as Exhibit 99.1?

Exhibit 99.1 is a press release relating to ET-700.

What is the filing date of this 8-K report?

The filing date is April 27, 2026.

What is the CIK number for Eton Pharmaceuticals, Inc.?

The CIK number for Eton Pharmaceuticals, Inc. is 0001710340.

What is the primary SIC code listed for Eton Pharmaceuticals?

The primary SIC code listed is 2834 for Pharmaceutical Preparations.

Which items of the 8-K form are being reported on?

The report covers Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits).

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 27, 2026 regarding Eton Pharmaceuticals, Inc. (ETON).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.